Welcome to Minecraft Craft Mine: April Fool's Edition—where nothing makes sense and everything's absolutely bonkers! Expect upside-down worlds, exploding chickens, and gravity gone wild in this ...

Add Yahoo as a preferred source to see more of our stories on Google. TikTok @fizy_vizy_vlogs/TikTok @ehsan1630/TikTok (TikTok @fizy_vizy_vlogs/TikTok @ehsan1630/TikTok) In the days leading up to New ...

President Donald Trump on Monday launched a renewed attack on Federal Reserve Chair Jerome Powell, accusing Powell of "gross incompetence" and threatening to sue him over the costly renovation of the ...

Rea’s death was announced in a post on his social media pages. The message reads, “It is with great sadness that we announce the passing of our beloved Chris, who died peacefully earlier today ...

Chris Rea, the rock singer who was best known for hits including “Driving Home For Christmas” and “Fool (If You Think It’s Over),” has died following a short illness. He was 74. “It is with immense ...

While there is some risk with Adobe's stock because the company faces some challenges, its valuation looks compelling and it by no means is it in a dire situation. Adobe’s stock has been struggling ...

Most April Fool’s Day pranks end with someone being tricked, but BMW New Zealand flipped that script in 2015. Instead of fooling people, they rewarded one. A mysterious ad in the paper promised a new ...

Hive Digital Technologies only trades at $3 per share, while giving investors exposure to crypto and artificial intelligence. The crypto miner more than quadrupled its crypto mining revenue ...

Motley Fool Asset Management kicked off a fresh wave of product expansion, launching three new factor-focused ETFs on Tuesday, its first lineup in nearly four years. All of the funds are passively ...

Venture Global delivered mixed results and lowered full-year profit expectations. Customers are suing Venture Global over past undelivered cargoes, with a revived legal challenge during the month. But ...

The FDA has granted accelerated approval to Otsuka’s sibeprenlimab (Voyxact) for proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. The monoclonal ...